Demand is rising for the reimbursement of ‘Columvi,’ the first bispecific antibody treatment option for lymphoma, in Korea.

The Korea Leukemia Patients Organization has requested the CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL) Columvi (glofitamab) be redeliberated at the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee meeting that will be held in October. In addition, the organization urged the manufacturer, Roche Korea, to come up with a financial sharing plan to accelerate the drug’s reimbursement listing.

“Columvi is a third-line treatment that can be immediately used in situations where death can occur within a few